Document Detail


Infliximab in Crohn's disease: first anniversary clinical experience.
MedLine Citation:
PMID:  11151879     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: The aim of this study is to report on the first year experience with infliximab for Crohn's disease. METHODS: All Crohn's patients receiving infliximab at our institution in the first year of release were prospectively registered. Disease activity was scored at initial infusion, and at 1, 3, 7, and 12 wk. Results were tabulated separately for patients with luminal (L) or fistulous (F) Crohn's disease. Steroid withdrawal and adverse events were tabulated. RESULTS: One hundred twenty-nine patients were treated (81 L, 48 F). Mean number of infusions/patient were 2.38 L, 3.23 F. Median time to response and remission was 8 and 9 days L; 9 and 10 days F, respectively. Initial infusion course response and remission rates at 3 wk were 65% and 31% L; 78% and 24% F, respectively. Rates were higher if concurrently treated with 6-mercaptopurine or azathioprine and improved with subsequent infusions. Relapse occurred in 78% at a mean 8.5 wk L and in 71% at a mean of 12.2 wk F. Steroid tapering was seen in >90%, with 54% completely off steroids after a second infusion. Infusion-related reactions were seen in up to 24% of patients. The incidence of side effects did not differ if on concurrent immunomodulatory therapy. CONCLUSIONS: Clinical experience with infliximab closely parallels the results of the controlled clinical trials, and includes steroid-sparing effects.
Authors:
R D Cohen; J F Tsang; S B Hanauer
Related Documents :
23454159 - The impact of running versus interrupted anastomosis on rate of uretero-intestinal stri...
16201099 - Operative indications for patients with refractory or severe ulcerative colitis.
24589219 - The assessment of the stability in mandibular setback surgery related to spatial factor...
19295189 - Treatment of mediastinal fibrosis with mycophenolate mofetil.
12700959 - Long versus standard initial steroid therapy for children with the nephrotic syndromea ...
14716499 - Preoperative steroid administration: effect on morbidity among patients undergoing inte...
15255239 - Clinical characteristics and surgical outcomes of pseudophakic and aphakic retinal deta...
6884649 - Surgical treatment of non-critical right ventricular outflow tract obstruction with int...
24550039 - Comparison of flucytosine and fluconazole combined with amphotericin b for the treatmen...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  The American journal of gastroenterology     Volume:  95     ISSN:  0002-9270     ISO Abbreviation:  Am. J. Gastroenterol.     Publication Date:  2000 Dec 
Date Detail:
Created Date:  2001-01-09     Completed Date:  2001-02-01     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0421030     Medline TA:  Am J Gastroenterol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  3469-77     Citation Subset:  IM    
Affiliation:
Department of Medicine, University of Chicago Hospitals, Illinois, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
6-Mercaptopurine / therapeutic use
Adult
Antibodies, Monoclonal / administration & dosage,  therapeutic use*
Azathioprine / therapeutic use
Case-Control Studies
Crohn Disease / drug therapy,  therapy*
Female
Gastrointestinal Agents / administration & dosage,  therapeutic use*
Humans
Male
Prednisone / therapeutic use
Prospective Studies
Time Factors
Chemical
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Gastrointestinal Agents; 0/infliximab; 446-86-6/Azathioprine; 50-44-2/6-Mercaptopurine; 53-03-2/Prednisone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Intravenous azathioprine in severe ulcerative colitis: a pilot study.
Next Document:  Elevated thrombopoietin serum levels in patients with inflammatory bowel disease.